Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 480 participants.
Also called NCT07181382
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 480 participants
- Sponsor
- Registry
-
NCT07181382 -
2025-521777-13-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Israel
- Registry status
- Suspended
Technical summary
Registry record NCT07181382. Randomized; double masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Acronym
- SERANATA
- Condition
- Pulmonary Hypertension Associated With Interstitial Lung Disease
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Seralutinib
- Intervention (Device)
- Generic Dry Powder Inhaler
- Lead sponsor
- GB002, Inc.
- Collaborator
- Chiesi Farmaceutici S.p.A.
Record details
- Record id
cardio:ct-nct07181382- Content hash
13f66fcee53ea5fd9c68210e39077c11f3f33dd9dbb422fe15bc5329e26462b3